Search results
The ECCO e-Guide is a freely-accessible online platform for Healthcare Professionals in IBD, which aims to visualise the ECCO Guidelines as algorithms based primarily on the main UC and CD Guidelines of ECCO.
17 mar 2021 · The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern.
These are the first ECCO Guidelines to adopt the GRADE approach [Grading of Recommendations Assessment, Development, and Evaluation] in order to provide transparent, high-quality, evidence-based recommendations on medical treatment in CD.
Since the initiation of the first project in 2006, the ECCO Guidelines have become standard references for IBD management in Europe and around the world. The guidelines are freely accessible and available for download on the ECCO Website and on JCC Online.
Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content. The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website. ... In case of potential ...
With the new ECCO Guidelines on Therapeutics in CD (published in 2019) and UC (publication expected in 2021), the key policy of ECCO was confirmed - establishing that guidance given by the ECCO e-Guide is based on evidence and validated processes – which are properly referenced.
18 gru 2022 · These include the risk of cancers associated with IBD, the risk of cancers from therapies used to treat IBD, and the management of IBD in a patient with active or recent cancer. This guideline was created according to ECCO’s standardised methodology.
